Kapidex approved for GERD

KAPIDEX (Dexlansoprazole) 30mg, 60mg capsules from Takeda
KAPIDEX (Dexlansoprazole) 30mg, 60mg capsules from Takeda
The FDA has approved Kapidex (dexlansoprazole, from Takeda)  delayed release capsules for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE), and the maintenance of healed EE.  The approval is based on two identically designed, double-blind, eight-week, randomized, controlled trials in which Kapidex (60mg) produced high overall healing rates for EE at week eight when compared to lansoprazole 30mg and was generally well-tolerated.

Kapidex is a proton pump inhibitor (PPI) that utilizes a Dual Delayed Release (DDR) formulation designed to provide two separate releases of medication.  It will be available in 30mg and 60mg dosage strengths.

For more information call (877) 825-3327 or visit www.kapidex.com.